Please wait while the formulary information is being retrieved.
Drug overview for ABENOR HP (sulfacetamide sodium/niacinamide):
Generic name: SULFACETAMIDE SODIUM/NIACINAMIDE
Drug class: Acne Antibiotics
Therapeutic class: Dermatological
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: SULFACETAMIDE SODIUM/NIACINAMIDE
Drug class: Acne Antibiotics
Therapeutic class: Dermatological
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for ABENOR HP (sulfacetamide sodium/niacinamide) have been approved by the FDA:
Indications:
None.
Professional Synonyms:
None.
Indications:
None.
Professional Synonyms:
None.
The following dosing information is available for ABENOR HP (sulfacetamide sodium/niacinamide):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for ABENOR HP (sulfacetamide sodium/niacinamide):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Topical Sodium Sulfacetamide/Topical Silver SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Topical sodium sulfacetamide and topical silver are physically incompatible.(1,2) CLINICAL EFFECTS: Concurrent application of topical sodium sulfacetamide and topical silver preparations may result in decreased clinical effectiveness of the products.(1,2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Avoid using topical silver preparations on the same location as topical sodium sulfacetamide products.(1,2) DISCUSSION: Topical sodium sulfacetamide and topical silver are physically incompatible.(1,2) |
ACESO AG, ACTICOAT, ACTICOAT 7, ACTICOAT FLEX 3, ACTICOAT FLEX 7, ACTICOAT SURGICAL, ALLEVYN AG, ALLEVYN AG ADHESIVE, ALLEVYN AG GENTLE, AZADROX, BASADROX, BIOSTEP AG, COLLATYL, DYNAFOAM AG, DYNAGINATE AG, NORMLGEL AG, PIVOT SILVER ALGINATE, PURACOL PLUS AG, RESTORE, RESTORE CALCIUM ALGINATE, SILIGENTLE AG, SILVADENE, SILVASORB, SILVER NITRATE, SILVER NITRATE APPLICATOR, SILVER PROTEIN, SILVER SULFADIAZINE, SILVRSTAT, SOLOX GEL, SSD |
There are 0 moderate interactions.
The following contraindication information is available for ABENOR HP (sulfacetamide sodium/niacinamide):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 3 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Glucose-6-phosphate dehydrogenase (g6Pd) deficiency |
| Hemoglobin H disease |
| Hemolytic anemia from pyruvate kinase and g6PD deficiencies |
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| No disease contraindications |
The following adverse reaction information is available for ABENOR HP (sulfacetamide sodium/niacinamide):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 12 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Agranulocytosis Blood dyscrasias Erythema Glucose-6-phosphate dehydrogenase (g6Pd) deficiency anemia Hepatic necrosis Hypersensitivity drug reaction Pruritus of skin Skin irritation Skin rash Stevens-johnson syndrome Systemic lupus erythematosus Toxic epidermal necrolysis |
There are 0 less severe adverse reactions.
The following precautions are available for ABENOR HP (sulfacetamide sodium/niacinamide):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for ABENOR HP (sulfacetamide sodium/niacinamide):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ABENOR HP (sulfacetamide sodium/niacinamide)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool